Comparative Studies of Trastuzumab Deruxtecan (T-DXd) and Trastuzumab Emtansine (T-DM1): Revolutionizing the HER2-Positive and HER2-Low Therapeutic Landscape
International Journal of Research in Pharmacy and Allied Science · 2026 · 05 (05) · 127-146
DOI: 10.71431/ijrpas.2026.5509 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Research in Pharmacy and Allied Science, 2026. Verfasst von Sudeep M S und 1 weiteren Autor:innen.
Abstract (Originalsprache)
The clinical validation of second and third generation antibody-drug conjugates (ADCs) has significantly transformed the therapeutic approach to treating malignancies that express human epidermal growth factor receptor 2 (HER2). Trastuzumab emtansine (T-DM1), the first HER2-targeted ADC to receive approval, set a standard for delivering microtubule-inhibiting agents through a stable, non-cleavable linker. Nonetheless, its effectiveness is often limited by poor membrane permeability, which reduces its efficacy in tumours with varied HER2 expression. Trastuzumab deruxtecan (T-DXd) marks a pivotal advancement in engineering, featuring a cleavable peptide linker, a notably higher drug-to-antibody ratio of 8:1, and a membrane-permeable topoisomerase I inhibitor payload. This review offers an in-depth comparative analysis of these two agents, integrating data from key trials such as DESTINY-Breast03, DESTINY-Breast05, and DESTINY-Breast06. We assess the pharmacological strategies that enable T-DXd to overcome resistance to T-DM1, particularly focusing on the bystander killing effect and the induction of immunogenic cell death. Furthermore, the analysis explores the expansion of the therapeutic target into HER2-low and HER2-ultralow categories, a shift uniquely facilitated by T-DXd's architecture. Shifting safety paradigms, including the risk of interstitial lung disease for T-DXd versus the manageable hepatobiliary and hematologic toxicities of T-DM1, are assessed to provide a framework for optimal therapeutic sequencing in the modern ADC era.
Zitieren
APA
S, S. M., & S, B. (2026). Comparative Studies of Trastuzumab Deruxtecan (T-DXd) and Trastuzumab Emtansine (T-DM1): Revolutionizing the HER2-Positive and HER2-Low Therapeutic Landscape. International Journal of Research in Pharmacy and Allied Science, 05(05), 127-146. https://doi.org/10.71431/ijrpas.2026.5509
Vancouver
S SM, S B. Comparative Studies of Trastuzumab Deruxtecan (T-DXd) and Trastuzumab Emtansine (T-DM1): Revolutionizing the HER2-Positive and HER2-Low Therapeutic Landscape. International Journal of Research in Pharmacy and Allied Science. 2026;05(05):127-146. doi:10.71431/ijrpas.2026.5509
BibTeX
@article{S2026,
author = {S, Sudeep M and S, Bindhu},
title = {Comparative Studies of Trastuzumab Deruxtecan (T-DXd) and Trastuzumab Emtansine (T-DM1): Revolutionizing the HER2-Positive and HER2-Low Therapeutic Landscape},
journal = {International Journal of Research in Pharmacy and Allied Science},
year = {2026},
volume = {05},
number = {05},
pages = {127--146},
doi = {10.71431/ijrpas.2026.5509}
}
EUVIMED